**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 91240

**Manuscript Type:** EDITORIAL

**Gut microbiota and female health**

Wang MY *et al*. Gut microbiota dysbiosis in female diseases

Meng-Yao Wang, Li-Xuan Sang, Si-Yu Sun

**Meng-Yao Wang, Li-Xuan Sang,** Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China

**Si-Yu Sun,** Department of Gastroenterology, Endoscopic Center, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Author contributions:** Sang LX and Sun SY designed the editorial; Wang MY wrote the draft; Sang LX revised the article for important intellectual content; Sun SY approved the final version, and each author contributed important intellectual content during manuscript drafting and revision.

**Supported by** Science and Technology Plan of Liaoning Province, No. 2022JH2/101500063.

**Corresponding author: Si-Yu Sun, MD, PhD, Chief Doctor, Director, Professor,** Department of Gastroenterology, Endoscopic Center, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. sun-siyu@163.com

**Received:** December 25, 2023

**Revised:** January 10, 2024

**Accepted:** March 5, 2024

**Published online:**

**Abstract**

The gut microbiota is recognized as an endocrine organ with the capacity to influence distant organs and associated biological pathways. Recent advancements underscore the critical role of gut microbial homeostasis in female health; with dysbiosis potentially leading to diseases among women such as polycystic ovarian syndrome, endometriosis, breast cancer, cervical cancer, and ovarian cancer *etc.* Despite this, there has been limited discussion on the underlying mechanisms. This editorial explores the three potential mechanisms through which gut microbiota dysbiosis may impact the development of diseases among women, namely, the immune system, the gut microbiota-estrogen axis, and the metabolite pathway. We focused on approaches for treating diseases in women by addressing gut microbiota imbalances through probiotics, prebiotics supplementation, and fecal microbiota transplantation (FMT). Future studies should focus on determining the molecular mechanisms underlying associations between dysbiosis of gut microbiota and female diseases to realize precision medicine, with FMT emerging as a promising intervention.

**Key Words:** Gut microbiota; Female health; Estrogen; Polycystic ovarian syndrome; Endometriosis

Wang MY, Sang LX, Sun SY. Gut microbiota and female health. *World J Gastroenterol* 2024; In press

**Core Tip:** Maintaining intestinal microbial homeostasis is essential for human health. Dysbiosis of gut microbiota has been demonstrated in patients with polycystic ovarian syndrome, endometriosis, breast cancer, cervical cancer, and ovarian cancer, disordered gut microbiota may affect the occurrence and development of these diseases through the immune system, estrogen, or metabolite pathways. In the future, maintaining gut microbiota homeostasis may be a promising treatment.

**INTRODUCTION**

The human body contains trillions of microbes, rapidly diversifying after birth. Recent developments in genome sequencing, transcriptome analysis, and metabolomics have enabled researchers to explore the microbiota in more detail, particularly their functions. The gut microbiota plays a pivotal role in nutrient transformation and absorption, maintaining vital interactions with multiple tissues and organs, an indispensable factor for human health. The primary bacteria found in the gut are *Firmicutes* and *Bacteroidetes*, accounting for 90% of the flora in the gut[1], other bacterial constituents include *Actinobacteria* and *Proteobacteria*.

While a universally healthy gut microbiota remains undefined, dysbiosis has been associated with diseases ranging from irritable bowel syndrome to cancer. Previous studies have reported sex differences in the distribution of gut microbiota and disease prevalence[2], of which, the female gut microbiota emerges as a compelling area for investigation. Marano *et al*[3] underscore the strategic role of gut microbiota in crucial life stages for women, from childhood through adolescence, fertile age to pregnancy-partum, and up to menopause. This editorial aimed to discuss the potential mechanisms and therapeutic targets associated with the impact of gut microbiota dysbiosis on female diseases.

**POSSIBLE MECHANISMS OF GUT MICROBIOTA DYSBIOSIS AFFECTING FEMALE HEALTH**

***Immune system***

The gut microbiota can both promote and inhibit inflammatory response by influencing inflammatory factors, thus affecting the onset and progression of female diseases. In a study by Xu *et al*[4], ovarian cancer cells transplanted into mice with gut microbiota dysbiosis demonstrated increased xenograft tumor sizes. This dysbiosis stimulated macrophages, resulting in increased circulating levels of interleukin (IL)-6 and tumor necrosis factor-α, thus inducing the progression of ovarian cancer epithelial-mesenchymal transition[4]. One study examined the gut microbiota in patients with preeclampsia, revealing that *Akkermansia muciniphila* significantly suppressed inflammation and alleviated preeclamptic symptoms in rats by promoting autophagy and M2 polarization of macrophages in the placental bed[5]. Dysbiotic shifts in the gut microbiota are associated with increased gut permeability, leading to increased translocation of bacterial endotoxins, primarily lipopolysaccharide (LPS)[6]. The activation of the innate immune system through toll-like receptor 4 by LPS increases the expression of proinflammatory cytokines *via* nuclear factor κB translocation[7].

***Gut microbiota - estrogen axis***

In premenopausal women, ovaries use cholesterol derived from saturated fats for estrogen synthesis. Following menopause, adipose tissue, adrenal glands, and other organs convert circulating androgens into estrogens through the aromatase enzyme[8,9]. As shown in Figure 1, circulating estrogens undergo conjugation in the liver through glucuronidation or sulfonation, facilitating their excretion in bile, urine, and stool. The gut microbiota significantly influences estrogen levels by secreting β-glucuronidase (GUS), an enzyme that converts conjugated estrogen into deconjugated estrogen in the gastrointestinal tract. This transformation allows it to bind to estrogen receptors, initiating downstream signaling and physiological effects[10,11]. In the lower female reproductive tract, estrogen regulates the microenvironment by increasing epithelial thickness, glycogen levels, mucus secretion, and indirectly lowering vaginal pH through the promotion of *Lactobacilli* abundance and lactic acid production[12]. Additionally, estrogen can modify gut epithelial barrier integrity[13].

Decreased GUS activity may lead to reduced deconjugation of estrogen, resulting in decreased circulating estrogen levels and contributing to pathologies such as obesity and polycystic ovarian syndrome (PCOS). In contrast, increased GUS activity can elevate estrogen levels, leading to conditions such as endometriosis and cancer[14,15]. Endogenous estrogen is a major factor in the development of postmenopausal breast cancer. Certain bacterial genera and species in the human gut, including *Bacteroides, Escherichia*, and *Lactobacillus*, contain genes encoding GUS[16]. In a study on mice with letrozole-induced PCOS, serum estradiol levels positively correlated with the abundance of *Bifidobacterium* and *Bacteroides*, while negatively correlating with the abundance of *Prevotella*[17]. The investigation by Shin *et al*[18] on 26 healthy women revealed that those in the high-estradiol group harbored a more diverse gut microbiota compared to the low- and medium-estradiol groups. The drop in serum estradiol concentration was attributed to the relative overabundance of *Slackia* and *Butyricimonas*[18]. Another study found a significant and positive association between non-ovarian urine estrogen levels and *Clostridia* taxa in the *Firmicutes* (including *non-Clostridiales* and three genera in the family *Ruminococcaceae*)[19].

***Metabolite pathway***

Through the breakdown of organic matter, gut microbiota produces metabolites such as short-chain fatty acids (SCFA) and bile acids. SCFAs, including acetic acid, propionic acid, and butyric acid, provide energy for colon cells, regulate the intestinal barrier, and influence the inflammatory response[20-23]. *Firmicutes* predominantly synthesize butyrate[24], while *Bacteroides* are major producers of acetate and propionate[25]. Butyric acid has been shown to regulate progesterone and estradiol secretion through the cAMP signaling pathway in porcine granulosa cells[26]. The study by Liu *et al*[27] demonstrated that supplementing with butyrate can alleviate nonalcoholic fatty liver disease in ovariectomized mice. One study found that SCFAs have anti-inflammatory properties mediated through the G protein-coupled receptor pathway and histone acetylase[28]. Notably, SCAFs may have anti-cancer properties in cervical cancer through the activation of free fatty acid receptor 2[29].

Bile acid plays an important role in maintaining intestinal homeostasis, regulating lipid and carbohydrate metabolism, and influencing immune function. The study by Qi *et al*[30] reported that elevated levels of *Bacteroides vulgatus* were observed in the gut microbiota of individuals with PCOS, and this elevation was accompanied by reduced levels of glycodeoxycholic acid and tauroursodeoxycholic acid. The study found that glycodeoxycholic acid induced intestinal group 3 innate lymphoid cell IL-22 secretion through GATA binding protein 3. IL-22, in turn, improved the PCOS phenotype[30]. In an *in vitro* experiment, it was demonstrated that urolithin A reduces the Rac1 and PAK1 activity, leading to a decrease in actin polymerization and consequently reducing cell migration in human endometrial carcinoma cells[31], urolithin A may offer new avenues for the development of novel cancer therapeutics.

**CHANGES OF GUT MICROBIOTA IN PATIENTS**

***PCOS***

PCOS is a prevalent endocrine disorder in women, characterized by symptoms such as anovulation, obesity, insulin resistance, and hyperandrogenism. Tremellen and Pearce[32] highlighted that disturbances in the gut microbiota resulting from a poor diet can lead to increased gut mucosal permeability. Subsequently, this allows LPS from Gram-negative colonic bacteria to enter the systemic circulation. The subsequent activation of the immune system interferes with insulin receptor function, elevating serum insulin levels, consequently contributing to increased androgen production by the ovaries and disruption of normal follicle development[32]. A study involving 18 obese patients with PCOS and 15 obese women without PCOS revealed that the richness and diversity of gut microbiota were lower in the obese PCOS group compared to the control group, *Lachnoclostridium*, *Fusobacterium*, *Coprococcus\_2*, and *Tyzzerela 4* were identified as the characteristic genera in obese patients with PCOS[33]. Additionally, mice transplanted with stool from women with PCOS exhibited fewer pups compared to mice transplanted with stool from healthy controls[30]. Modulating gut microbiota could hold significant value for the treatment of PCOS[34,35].

***Endometriosis***

Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial tissue (glands and stroma) outside the uterus, significantly impacting the quality of life of women of childbearing age[36]. Although endometriosis is known to be estrogen-dependent, studies have revealed that the growth of ectopic lesions persists even in ovariectomized animals. This suggests that in addition to ovarian steroids, the innate immune system of the pelvic environment can also regulate the growth of ectopic lesions in endometriosis[37]. Notably, gut microbiota dysbiosis has been associated with the occurrence and development of endometriosis. A study involving 14 women with histologically confirmed stage 3/4 endometriosis and 14 healthy controls demonstrated significant decreases in the genera *Sneathia*, *Barnesella*, and *Gardnerella* in stool samples of the endometriosis group[38]. Two patients in the endometriosis group exhibited higher levels of *Escherichia*/*Shigella* in stool, and subsequent follow-up revealed severe bowel involvement by endometriosis in these patients[38]. Moreover, a study using antibiotic-induced microbiota-depleted (MD) mice to investigate endometriosis progression demonstrated that MD mice exhibited reduced endometriotic lesion growth, and the transplantation of gut microbiota through oral gavage of feces from mice with endometriosis caused the endometriotic lesion growth[39]. Thus, these findings underscore the close relationship between the occurrence and development of endometriosis and gut microbiota.

***Cancer***

Dysbiosis of microbiota can impact the occurrence and progression of tumors by regulating host immune response and inflammatory pathways. Breast cancer is one of the most prevalent malignant tumors among women worldwide and is closely linked to estrogen levels. The gut microbiota plays a role in deconjugating estrogens through the bacterial secretion of GUS, enabling estrogens to bind to estrogen receptors. Subsequently, the activation of estrogen receptors increases the number of G0/G1 cells entering the cell cycle, promoting cell proliferation, which is particularly well-defined in breast cancer[40]. The study conducted by Bobin-Dubigeon *et al*[41] demonstrated a reduction in gut microbiota diversity, a relative enrichment in *Firmicutes*, and a depletion in *Bacteroidetes* among patients with breast cancer as compared to those of healthy women. In another controlled study, patients with breast cancer exhibited a lower abundance of some microbial taxa, including *Bacteroidetes phylum*, *Firmicutes phylum*, *Verrucomicrobia phylum*, *Clostridium genus*, *Shigella genus*, *Bifidobacterium genus*, *Akkermansia muciniphila*, *Clostridium perfringens*, *Escherichia coli*, *Bacteroides uniformis*, *Clostridium hathewayi*, and *Faecalibacterium prausnitzii*[42].

Cervical cancer ranks as the fourth most common cancer in terms of morbidity and mortality, primarily attributed to human papillomavirus infection. In a study involving 42 patients with cervical cancer, gut microbiota 16S rDNA analysis revealed differences in both α and β diversity between the patient group and the control group[43]. The patient group exhibited a higher abundance of *Prevotella*, *Porphyromonas*, and *Dialister*, while the control group showed a higher abundance of *Bacteroides*, *Alistipes*, and members of the *Lachnospiracea* family[43]. Additionally, Chang *et al*[44] conducted an enrichment analysis of gut microbiota from patients with cervical cancer patients and healthy controls and found that the functions of the differentially expressed genes in the two groups, primarily associated with REDOX reactions, biosynthesis of other secondary metabolites, and amino acid transport and metabolism.

Ovarian cancer, with the highest mortality among female genital tract malignancies, is often diagnosed at advanced stages with metastasis. Endoscopic ultrasound is a non-invasive and accurate method for the early diagnosis of early carcinoma in the upper gastrointestinal tract and liver diseases[45,46]. Additionally, this tool is effective in detecting ovarian cancer infiltration of surrounding organs[47]. Xu *et al*[4] demonstrated *in vitro* that gut microbiota dysbiosis can promote the growth of ovarian cancer cells and induce epithelial-mesenchymal transition. This underscores the need for further exploration of the role of gut microbiota in the occurrence and development of various tumors. Table 1 summarizes the list of studies that highlighted the gut microbiota changes in patients with PCOS, endometriosis, breast cancer, cervical cancer, and ovarian cancer.

**THERAPY**

Probiotics have emerged as a modulator of gut microbiota. Recently, probiotics have been successfully used in the regulation of disrupted gut microbiota and the improvement of diseases such as gestational diabetes mellitus (GDM) and endometriosis. In a prospective study involving 256 pregnant women randomized to receive probiotics or a placebo during the first trimester, the probiotic intervention resulted in a reduced incidence of GDM[53]. Additionally, oral administration of lactic acid bacteria was found to alleviate endometriosis-related pain[54]. In a study by He *et al*[34], a PCOS-induced rat model treated through letrozole treatment showed that a 4-wk strain intervention, particularly with *Lactobacillus plantarum* HL2, was protective against PCOS-like pathological changes in the ovaries. Prebiotics are defined as a nondigestible food ingredient that selectively stimulates the growth and/or activity of specific bacteria in the colon; thus, improving host health[55]. Prebiotics improve the balance of gut microbiota and produce various beneficial effects on the human host, such as improving insulin resistance[56] and regulating intestinal immunity[57].

The technology of fecal microbiota transplantation (FMT) has gradually matured and found applications in various complex intestinal diseases. However, there has been limited research on the use of FMT for the treatment of gynecological diseases. In a study, rats with PCOS were observed to have lower levels of *Lactobacillus* and *Clostridium*, and higher levels of *Prevotella* compared to control rats[35]. Following treatment with FMT and *Lactobacillus* from healthy rats, the abnormal estrous cycle improved, and androgen biosynthesis decreased in all rats in the FMT group and 75% of the rats in the *Lactobacillus* group. Moreover, ovarian morphology normalized, and the composition of the recovered gut microbiota in the FMT and *Lactobacillus*-treated groups demonstrated an increase in *Lactobacillus* and *Clostridium* and a decrease in *Prevotella*[35]. Huang *et al*[2] performed ovariectomy on 12-wk-old mice and subsequent follow-up revealed vaginal atrophy and disrupted intestinal microbial balance at 4 wk post-operation. Subsequent transplantation of gut microbiota from normal female mice to ovariectomized mice resulted in enhanced proliferation of vaginal epithelium and significant alleviation of epithelial atrophy. The abundance of bacteria positively influencing vaginal epithelial regeneration (*Proteobacteria*, *Verrucomicrobia*, *Akkermansia*) increased as observed in the study. Therefore, further research on FMT could offer a new alternative treatment for gynecological diseases.

**CONCLUSION**

The impact of gut microbiota on the body’s immune system and hormonal balance is significant, dysbiosis of gut microbiota has been associated with the promotion of common gynecological diseases, such as PCOS, endometriosis, and malignant tumors. Conversely, these diseases can further disrupt the balance of gut microbiota. Interventions targeting the imbalanced gut microbiota, including the use of probiotics, prebiotics, and FMT, have shown promising results in animal experimental models. This approach offers a new perspective on the treatment of gynecological diseases, although further clinical studies are necessary to validate these findings. In the future, exploring the possibility of “matching” FMT donors and recipients or using bioengineering to synthesize bacterial solutions for precise disease treatment is worth further exploration.

**ACKNOWLEDGEMENTS**

We would like to thank the Department of Gastroenterology and Endoscopic Center of Shengjing Hospital of China Medical University for technical assistance.

**REFERENCES**

1 **Adak A**, Khan MR. An insight into gut microbiota and its functionalities. *Cell Mol Life Sci* 2019; **76**: 473-493 [PMID: 30317530 DOI: 10.1007/s00018-018-2943-4]

2 **Huang J**, Shan W, Li F, Wang Z, Cheng J, Lu F, Guo E, Beejadhursing R, Xiao R, Liu C, Yang B, Li X, Fu Y, Xi L, Wang S, Ma D, Chen G, Sun C. Fecal microbiota transplantation mitigates vaginal atrophy in ovariectomized mice. *Aging (Albany NY)* 2021; **13**: 7589-7607 [PMID: 33658399 DOI: 10.18632/aging.202627]

3 **Marano G**, Traversi G, Gaetani E, Gasbarrini A, Mazza M. Gut microbiota in women: The secret of psychological and physical well-being. *World J Gastroenterol* 2023; **29**: 5945-5952 [PMID: 38131001 DOI: 10.3748/wjg.v29.i45.5945]

4 **Xu S**, Liu Z, Lv M, Chen Y, Liu Y. Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer. *Pathog Dis* 2019; **77** [PMID: 30916767 DOI: 10.1093/femspd/ftz019]

5 **Jin J**, Gao L, Zou X, Zhang Y, Zheng Z, Zhang X, Li J, Tian Z, Wang X, Gu J, Zhang C, Wu T, Wang Z, Zhang Q. Gut Dysbiosis Promotes Preeclampsia by Regulating Macrophages and Trophoblasts. *Circ Res* 2022; **131**: 492-506 [PMID: 35950704 DOI: 10.1161/CIRCRESAHA.122.320771]

6 **Cani PD**, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. *Gut Microbes* 2012; **3**: 279-288 [PMID: 22572877 DOI: 10.4161/gmic.19625]

7 **Creely SJ**, McTernan PG, Kusminski CM, Fisher fM, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007; **292**: E740-E747 [PMID: 17090751 DOI: 10.1152/ajpendo.00302.2006]

8 **Arnone AA**, Cook KL. Gut and Breast Microbiota as Endocrine Regulators of Hormone Receptor-positive Breast Cancer Risk and Therapy Response. *Endocrinology* 2022; **164** [PMID: 36282876 DOI: 10.1210/endocr/bqac177]

9 **Zhu BT**, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. *Carcinogenesis* 1998; **19**: 1-27 [PMID: 9472688 DOI: 10.1093/carcin/19.1.1]

10 **Chadchan SB**, Singh V, Kommagani R. Female reproductive dysfunctions and the gut microbiota. *J Mol Endocrinol* 2022; **69**: R81-R94 [PMID: 35900833 DOI: 10.1530/JME-21-0238]

11 **Salliss ME**, Farland LV, Mahnert ND, Herbst-Kralovetz MM. The role of gut and genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain. *Hum Reprod Update* 2021; **28**: 92-131 [PMID: 34718567 DOI: 10.1093/humupd/dmab035]

12 **Muhleisen AL**, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. *Maturitas* 2016; **91**: 42-50 [PMID: 27451320 DOI: 10.1016/j.maturitas.2016.05.015]

13 **Homma H**, Hoy E, Xu DZ, Lu Q, Feinman R, Deitch EA. The female intestine is more resistant than the male intestine to gut injury and inflammation when subjected to conditions associated with shock states. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G466-G472 [PMID: 15499084 DOI: 10.1152/ajpgi.00036.2004]

14 **Plottel CS**, Blaser MJ. Microbiome and malignancy. *Cell Host Microbe* 2011; **10**: 324-335 [PMID: 22018233 DOI: 10.1016/j.chom.2011.10.003]

15 **Baker JM**, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. *Maturitas* 2017; **103**: 45-53 [PMID: 28778332 DOI: 10.1016/j.maturitas.2017.06.025]

16 **Kwa M**, Plottel CS, Blaser MJ, Adams S. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. *J Natl Cancer Inst* 2016; **108** [PMID: 27107051 DOI: 10.1093/jnci/djw029]

17 **Wu YX**, Yang XY, Han BS, Hu YY, An T, Lv BH, Lian J, Wang TY, Bao XL, Gao L, Jiang GJ. Naringenin regulates gut microbiota and SIRT1/ PGC-1ɑ signaling pathway in rats with letrozole-induced polycystic ovary syndrome. *Biomed Pharmacother* 2022; **153**: 113286 [PMID: 35724506 DOI: 10.1016/j.biopha.2022.113286]

18 **Shin JH**, Park YH, Sim M, Kim SA, Joung H, Shin DM. Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. *Res Microbiol* 2019; **170**: 192-201 [PMID: 30940469 DOI: 10.1016/j.resmic.2019.03.003]

19 **Flores R**, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, Gajer P, Ravel J, Goedert JJ. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. *J Transl Med* 2012; **10**: 253 [PMID: 23259758 DOI: 10.1186/1479-5876-10-253]

20 **Ziętek M**, Celewicz Z, Szczuko M. Short-Chain Fatty Acids, Maternal Microbiota and Metabolism in Pregnancy. *Nutrients* 2021; **13** [PMID: 33918804 DOI: 10.3390/nu13041244]

21 **Kelly CJ**, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, Weir TL, Ehrentraut SF, Pickel C, Kuhn KA, Lanis JM, Nguyen V, Taylor CT, Colgan SP. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. *Cell Host Microbe* 2015; **17**: 662-671 [PMID: 25865369 DOI: 10.1016/j.chom.2015.03.005]

22 **Inan MS**, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. *Gastroenterology* 2000; **118**: 724-734 [PMID: 10734024 DOI: 10.1016/s0016-5085(00)70142-9]

23 **Rivière A**, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol* 2016; **7**: 979 [PMID: 27446020 DOI: 10.3389/fmicb.2016.00979]

24 **Gasaly N**, Hermoso MA, Gotteland M. Butyrate and the Fine-Tuning of Colonic Homeostasis: Implication for Inflammatory Bowel Diseases. *Int J Mol Sci* 2021; **22** [PMID: 33802759 DOI: 10.3390/ijms22063061]

25 **Macfarlane S**, Macfarlane GT. Regulation of short-chain fatty acid production. *Proc Nutr Soc* 2003; **62**: 67-72 [PMID: 12740060 DOI: 10.1079/PNS2002207]

26 **Lu N**, Li M, Lei H, Jiang X, Tu W, Lu Y, Xia D. Butyric acid regulates progesterone and estradiol secretion via cAMP signaling pathway in porcine granulosa cells. *J Steroid Biochem Mol Biol* 2017; **172**: 89-97 [PMID: 28602959 DOI: 10.1016/j.jsbmb.2017.06.004]

27 **Liu L**, Fu Q, Li T, Shao K, Zhu X, Cong Y, Zhao X. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. *PLoS One* 2022; **17**: e0262855 [PMID: 35108315 DOI: 10.1371/journal.pone.0262855]

28 **Zhang Z**, Zhang H, Chen T, Shi L, Wang D, Tang D. Regulatory role of short-chain fatty acids in inflammatory bowel disease. *Cell Commun Signal* 2022; **20**: 64 [PMID: 35546404 DOI: 10.1186/s12964-022-00869-5]

29 **Matsuya-Ogawa M**, Shibata T, Itoh H, Murakami H, Yaguchi C, Sugihara K, Kanayama N. Oncoprotective Effects of Short-Chain Fatty Acids on Uterine Cervical Neoplasia. *Nutr Cancer* 2019; **71**: 312-319 [PMID: 30836015 DOI: 10.1080/01635581.2019.1578388]

30 **Qi X**, Yun C, Sun L, Xia J, Wu Q, Wang Y, Wang L, Zhang Y, Liang X, Wang L, Gonzalez FJ, Patterson AD, Liu H, Mu L, Zhou Z, Zhao Y, Li R, Liu P, Zhong C, Pang Y, Jiang C, Qiao J. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. *Nat Med* 2019; **25**: 1225-1233 [PMID: 31332392 DOI: 10.1038/s41591-019-0509-0]

31 **Alauddin M**, Okumura T, Rajaxavier J, Khozooei S, Pöschel S, Takeda S, Singh Y, Brucker SY, Wallwiener D, Koch A, Salker MS. Gut Bacterial Metabolite Urolithin A Decreases Actin Polymerization and Migration in Cancer Cells. *Mol Nutr Food Res* 2020; **64**: e1900390 [PMID: 31976617 DOI: 10.1002/mnfr.201900390]

32 **Tremellen K**, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome. *Med Hypotheses* 2012; **79**: 104-112 [PMID: 22543078 DOI: 10.1016/j.mehy.2012.04.016]

33 **Zhou L**, Ni Z, Yu J, Cheng W, Cai Z, Yu C. Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome. *Front Endocrinol (Lausanne)* 2020; **11**: 628 [PMID: 33013704 DOI: 10.3389/fendo.2020.00628]

34 **He Y**, Wang Q, Li X, Wang G, Zhao J, Zhang H, Chen W. Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota. *Food Funct* 2020; **11**: 5192-5204 [PMID: 32441726 DOI: 10.1039/c9fo02554e]

35 **Guo Y**, Qi Y, Yang X, Zhao L, Wen S, Liu Y, Tang L. Association between Polycystic Ovary Syndrome and Gut Microbiota. *PLoS One* 2016; **11**: e0153196 [PMID: 27093642 DOI: 10.1371/journal.pone.0153196]

36 **Taylor HS**, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. *Lancet* 2021; **397**: 839-852 [PMID: 33640070 DOI: 10.1016/S0140-6736(21)00389-5]

37 **Wang Y**, Nicholes K, Shih IM. The Origin and Pathogenesis of Endometriosis. *Annu Rev Pathol* 2020; **15**: 71-95 [PMID: 31479615 DOI: 10.1146/annurev-pathmechdis-012419-032654]

38 **Ata B**, Yildiz S, Turkgeldi E, Brocal VP, Dinleyici EC, Moya A, Urman B. The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls. *Sci Rep* 2019; **9**: 2204 [PMID: 30778155 DOI: 10.1038/s41598-019-39700-6]

39 **Chadchan SB**, Naik SK, Popli P, Talwar C, Putluri S, Ambati CR, Lint MA, Kau AL, Stallings CL, Kommagani R. Gut microbiota and microbiota-derived metabolites promotes endometriosis. *Cell Death Discov* 2023; **9**: 28 [PMID: 36693853 DOI: 10.1038/s41420-023-01309-0]

40 **Doisneau-Sixou SF**, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. *Endocr Relat Cancer* 2003; **10**: 179-186 [PMID: 12790780 DOI: 10.1677/erc.0.0100179]

41 **Bobin-Dubigeon C**, Luu HT, Leuillet S, Lavergne SN, Carton T, Le Vacon F, Michel C, Nazih H, Bard JM. Faecal Microbiota Composition Varies between Patients with Breast Cancer and Healthy Women: A Comparative Case-Control Study. *Nutrients* 2021; **13** [PMID: 34444865 DOI: 10.3390/nu13082705]

42 **Caleça T**, Ribeiro P, Vitorino M, Menezes M, Sampaio-Alves M, Mendes AD, Vicente R, Negreiros I, Faria A, Costa DA. Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?-"BiotaCancerSurvivors": A Case-Control Study. *Cancers (Basel)* 2023; **15** [PMID: 36765550 DOI: 10.3390/cancers15030594]

43 **Sims TT**, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. *Gynecol Oncol* 2019; **155**: 237-244 [PMID: 31500892 DOI: 10.1016/j.ygyno.2019.09.002]

44 **Chang L**, Qiu L, Lei N, Zhou J, Guo R, Gao F, Dong S, Chen M, Wu F, Qin B. Characterization of fecal microbiota in cervical cancer patients associated with tumor stage and prognosis. *Front Cell Infect Microbiol* 2023; **13**: 1145950 [PMID: 36909733 DOI: 10.3389/fcimb.2023.1145950]

45 **Chen H**, Wang X, Shao S, Zhang J, Tan X, Chen W. Value of EUS in determining infiltration depth of early carcinoma and associated precancerous lesions in the upper gastrointestinal tract. *Endosc Ultrasound* 2022; **11**: 503-510 [PMID: 36537388 DOI: 10.4103/EUS-D-21-00218]

46 **Jearth V**, Sundaram S, Rana SS. Diagnostic and interventional EUS in hepatology: An updated review. *Endosc Ultrasound* 2022; **11**: 355-370 [PMID: 36255023 DOI: 10.4103/EUS-D-22-00027]

47 **Carvalho J Jr**, Formighieri B, Filippi S, Rossini L. Location of recurrent asymptomatic ovarian cancer through endoscopic ultrasound. *Endosc Ultrasound* 2015; **4**: 63-65 [PMID: 25789287 DOI: 10.4103/2303-9027.151353]

48 **Liu R**, Zhang C, Shi Y, Zhang F, Li L, Wang X, Ling Y, Fu H, Dong W, Shen J, Reeves A, Greenberg AS, Zhao L, Peng Y, Ding X. Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome. *Front Microbiol* 2017; **8**: 324 [PMID: 28293234 DOI: 10.3389/fmicb.2017.00324]

49 **Svensson A**, Brunkwall L, Roth B, Orho-Melander M, Ohlsson B. Associations Between Endometriosis and Gut Microbiota. *Reprod Sci* 2021; **28**: 2367-2377 [PMID: 33660232 DOI: 10.1007/s43032-021-00506-5]

50 **Huang L**, Liu B, Liu Z, Feng W, Liu M, Wang Y, Peng D, Fu X, Zhu H, Cui Z, Xie L, Ma Y. Gut Microbiota Exceeds Cervical Microbiota for Early Diagnosis of Endometriosis. *Front Cell Infect Microbiol* 2021; **11**: 788836 [PMID: 34950610 DOI: 10.3389/fcimb.2021.788836]

51 **Wang Z**, Wang Q, Zhao J, Gong L, Zhang Y, Wang X, Yuan Z. Altered diversity and composition of the gut microbiome in patients with cervical cancer. *AMB Express* 2019; **9**: 40 [PMID: 30904962 DOI: 10.1186/s13568-019-0763-z]

52 **Hu X**, Xu X, Zeng X, Jin R, Wang S, Jiang H, Tang Y, Chen G, Wei J, Chen T, Chen Q. Gut microbiota dysbiosis promotes the development of epithelial ovarian cancer via regulating Hedgehog signaling pathway. *Gut Microbes* 2023; **15**: 2221093 [PMID: 37282604 DOI: 10.1080/19490976.2023.2221093]

53 **Luoto R**, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. *Br J Nutr* 2010; **103**: 1792-1799 [PMID: 20128938 DOI: 10.1017/S0007114509993898]

54 **Khodaverdi S**, Mohammadbeigi R, Khaledi M, Mesdaghinia L, Sharifzadeh F, Nasiripour S, Gorginzadeh M. Beneficial Effects of Oral Lactobacillus on Pain Severity in Women Suffering from Endometriosis: A Pilot Placebo-Controlled Randomized Clinical Trial. *Int J Fertil Steril* 2019; **13**: 178-183 [PMID: 31310070 DOI: 10.22074/ijfs.2019.5584]

55 **Hutkins RW**, Krumbeck JA, Bindels LB, Cani PD, Fahey G Jr, Goh YJ, Hamaker B, Martens EC, Mills DA, Rastal RA, Vaughan E, Sanders ME. Prebiotics: why definitions matter. *Curr Opin Biotechnol* 2016; **37**: 1-7 [PMID: 26431716 DOI: 10.1016/j.copbio.2015.09.001]

56 **Kim YA**, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. *Nutr Res Rev* 2018; **31**: 35-51 [PMID: 29037268 DOI: 10.1017/S095442241700018X]

57 **Martyniak A**, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. *Biomolecules* 2021; **11** [PMID: 34944546 DOI: 10.3390/biom11121903]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 25, 2023

**First decision:** January 4, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Exbrayat JM, France **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Effects of gut microbiota on estrogen metabolism.** Estrogens are primarily produced in the ovaries, adrenal glands, and adipose tissue and circulate in the bloodstream and first undergo metabolism in the liver, where estrogens are conjugated. Conjugated estrogens are eliminated from the body by metabolic conversion to water-soluble molecules, which are excreted in urine or bile into the gut. The gut microbiota significantly influences estrogen levels by secreting β-glucuronidase (GUS), an enzyme that converts conjugated estrogen into deconjugated estrogen in the gastrointestinal tract. This transformation allows it to bind to estrogen receptors, initiating downstream signaling and physiological effects. Decreased GUS activity may lead to reduced deconjugation of estrogen, resulting in decreased circulating estrogen levels and contributing to pathologies such as obesity and polycystic ovarian syndrome. In contrast, increased GUS activity can elevate estrogen levels, leading to conditions such as endometriosis and cancer. IEC: Intestinal epithelial cell; GUS: β-glucuronidase; PCOS: Polycystic ovarian syndrome.

**Table 1 Gut microbiota alterations in polycystic ovarian syndrome endometriosis, breast cancer, cervical cancer, and ovarian cancer of the human studies**

|  |  |
| --- | --- |
| **Diseases** | **Changes in gut microbiota (human studies)** |
| **PCOS** | Increase: *Lachnoclostridium*, *Fusobacterium*, *Coprococcus\_2*, and *Tyzzerela 4*[33]; *Bacteroides*, *Escherichia/Shigella*,and *Streptococcus*[48] |
| Decrease: *Tenericutes* and *Firmicutes/Bacteroides ratio*[33]; *Akkermansia* and *Ruminococcaceae*[48] |
| **Endometriosis** | Increase: *Bacteroides*, *Parabacteroides Oscillospira*, and *Coprococccus*[49] |
| Decrease: *Paraprevotella* and *Lachnospira*[49]; *Clostridia Clostridiales*, *Lachnospiraceae Ruminococcus*, *Clostridiales*, *Lachnospiraceae*, and *Ruminococcaceae Ruminococcus*[50] |
| **Breast cancer** | Increase: *Firmicutes*, *Clostridium cluster IV*,and *cluster XIVa*[41] |
| Decrease: *Bacteroidetes*[41]; *Bacteroidetes phylum*, and *Verrucomicrobia phylum*[42] |
| **Cervical cancer** | Increase: *Prevotella*, *Porphyromonas*,and *Dialister*[43]; *Succinivibrio*, *Ruminococcus*, *Morganella*, *Shewanella*,and *Proteus*[51] |
| Decrease: *Bacteroides*, *Alistipes*,and *Lachnospiracea*[43]; *Phascolarctobacterium* and *Halomonas*[51] |
| **Ovarian cancer** | Increase: *Proteobacteria*[52] |
| Decrease: *Actinobacteria*, *Bifidobacterium*, and *Coprococcus*[52] |

PCOS: Polycystic ovarian syndrome.